Jiangsu Pengyao Pharmaceuticals, Inc.

To investigate the pharmacokinetic characteristics of loxoprofen sodium tablets (test preparation T, strength: 60 mg) provided by Jiangsu Pengyao Pharmaceutical Co., Ltd. after a single oral administration in healthy subjects under fasting and postprandial conditions and loxoprofen sodium tablets (reference preparation R, trade name: Lesong®, strength: 60 mg) certified by Daiichi Sankyo Pharmaceutical (Shanghai) Co., Ltd. after a single oral administration under the same conditions, to evaluate the bioequivalence and safety of the two preparations and to provide a basis for the registration application of the test preparation.

Main purpose: Using ketotifen fumarate tablets produced by Jiangsu Pengyao Pharmaceutical Co., Ltd. as the test preparation (T), and ketotifen fumarate tablets (Zaditen®) produced by Novartis Pharma Schweiz AG as the reference preparation (R), evaluate the human bioavailability of the test preparation and the reference preparation after a single oral administration in healthy subjects in the fasting and postprandial state, and evaluate the bioequivalence of the two preparations. Secondary purpose: Investigate the safety of the test preparation and the reference preparation after oral administration in healthy subjects.

1) To evaluate the bioequivalence of the test preparation carbamazepine tablets (produced by Jiangsu Pengyao Pharmaceutical Co., Ltd.) 200 mg and the reference preparation carbamazepine tablets (trade name: Delito®, produced by Beijing Novartis Pharmaceutical Co., Ltd.) 200 mg in healthy Chinese subjects under fasting and postprandial administration conditions; 2) To observe the safety of the test preparation and the reference preparation in healthy subjects.